Your browser is no longer supported. Please, upgrade your browser.
COO The Cooper Companies, Inc. daily Stock Chart
The Cooper Companies, Inc.
IndexS&P 500 P/E60.13 EPS (ttm)5.47 Insider Own0.20% Shs Outstand49.10M Perf Week-0.18%
Market Cap17.60B Forward P/E26.16 EPS next Y12.58 Insider Trans-5.54% Shs Float48.73M Perf Month-5.01%
Income272.40M PEG6.01 EPS next Q3.10 Inst Own91.60% Short Float1.37% Perf Quarter5.31%
Sales2.44B P/S7.21 EPS this Y29.20% Inst Trans0.65% Short Ratio2.57 Perf Half Y3.80%
Book/sh76.58 P/B4.30 EPS next Y31.46% ROA4.30% Target Price344.58 Perf Year5.05%
Cash/sh2.38 P/C138.11 EPS next 5Y10.00% ROE7.50% 52W Range236.68 - 371.59 Perf YTD2.40%
Dividend0.06 P/FCF98.57 EPS past 5Y10.80% ROI9.70% 52W High-11.46% Beta0.83
Dividend %0.02% Quick Ratio0.60 Sales past 5Y9.10% Gross Margin64.10% 52W Low39.01% ATR9.39
Employees12000 Current Ratio1.20 Sales Q/Q-14.90% Oper. Margin14.70% RSI (14)44.93 Volatility2.46% 2.75%
OptionableYes Debt/Eq0.50 EPS Q/Q-53.50% Profit Margin11.40% Rel Volume0.98 Prev Close325.46
ShortableYes LT Debt/Eq0.35 EarningsDec 03 AMC Payout1.10% Avg Volume259.15K Price329.01
Recom2.40 SMA20-1.20% SMA50-3.39% SMA2005.84% Volume252,892 Change1.09%
Jul-06-20Downgrade Robert W. Baird Outperform → Neutral $291
Mar-05-20Initiated Citigroup Neutral $360
Feb-01-19Upgrade Stephens Equal-Weight → Overweight $305
Jan-04-19Downgrade Goldman Neutral → Sell
Jul-30-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Apr-04-18Initiated Goldman Neutral $231
Dec-08-17Reiterated Stifel Buy $275 → $265
Sep-12-17Reiterated Stifel Buy $265 → $275
Sep-01-17Reiterated Piper Jaffray Overweight $265 → $280
Jul-21-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Jun-29-17Initiated Guggenheim Neutral
Jun-02-17Reiterated Stifel Buy $220 → $231
Dec-12-16Upgrade Wells Fargo Market Perform → Outperform
Sep-02-16Reiterated BMO Capital Markets Outperform $199 → $206
Aug-31-16Reiterated Stifel Buy $195 → $215
Jun-30-16Reiterated Stifel Buy $180 → $195
Jun-03-16Reiterated Jefferies Buy $175 → $190
Apr-15-16Upgrade Jefferies Hold → Buy
Dec-17-15Initiated Goldman Neutral
Dec-04-15Downgrade JP Morgan Overweight → Neutral
Nov-26-20 12:30PM  
Nov-24-20 08:21AM  
Nov-12-20 04:15PM  
Nov-10-20 09:23AM  
Nov-03-20 04:15PM  
Oct-27-20 07:59AM  
Oct-19-20 02:11PM  
Oct-09-20 08:00AM  
Oct-03-20 11:30AM  
Oct-01-20 07:50AM  
Sep-21-20 03:02PM  
Sep-14-20 10:02AM  
Sep-12-20 07:28AM  
Sep-10-20 07:15AM  
Sep-08-20 08:33AM  
Sep-07-20 02:03AM  
Sep-05-20 10:50AM  
Sep-04-20 03:50PM  
Sep-03-20 05:11PM  
Sep-02-20 10:13AM  
Aug-31-20 04:15PM  
Aug-26-20 12:30PM  
Aug-24-20 11:20AM  
Aug-19-20 04:15PM  
Aug-13-20 04:15PM  
Aug-06-20 04:15PM  
Aug-05-20 11:40AM  
Jul-20-20 04:02PM  
Jul-11-20 03:46PM  
Jul-09-20 04:15PM  
Jul-06-20 04:15PM  
Jul-02-20 09:34AM  
Jun-30-20 12:56PM  
Jun-25-20 08:13AM  
Jun-15-20 11:11AM  
Jun-09-20 05:06PM  
Jun-05-20 12:02PM  
Jun-04-20 05:35PM  
Jun-01-20 09:52AM  
May-28-20 01:33PM  
May-14-20 07:30AM  
May-07-20 04:15PM  
Apr-21-20 02:02PM  
Apr-13-20 09:45AM  
Apr-09-20 07:28AM  
Apr-04-20 11:30AM  
Apr-03-20 11:40AM  
Apr-01-20 04:15PM  
Mar-30-20 06:32AM  
Mar-18-20 11:40AM  
Mar-17-20 09:20PM  
Mar-13-20 09:49AM  
Mar-09-20 06:55PM  
Mar-06-20 09:53AM  
Mar-05-20 05:35PM  
Mar-03-20 09:26AM  
Feb-27-20 01:04PM  
Feb-26-20 12:10PM  
Feb-24-20 09:36AM  
Feb-18-20 04:15PM  
Feb-12-20 04:15PM  
Feb-11-20 04:15PM  
Feb-07-20 04:15PM  
Feb-04-20 04:15PM  
Jan-29-20 06:32AM  
Jan-09-20 04:20PM  
Jan-07-20 04:15PM  
Jan-04-20 11:30AM  
Jan-03-20 07:13AM  
Dec-19-19 04:15PM  
Dec-12-19 12:03AM  
Dec-09-19 04:15PM  
Dec-08-19 08:29AM  
Dec-06-19 08:21AM  
Dec-05-19 05:35PM  
Dec-03-19 08:24AM  
Dec-02-19 09:40AM  
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive option, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is based in San Ramon, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Auerbach Robert DSpecial Advisor to the CEOOct 08Sale350.002,538888,3001,403Oct 09 08:26 PM
PETERSMEYER GARY SDirectorOct 06Option Exercise162.691,000162,6902,338Oct 07 05:06 PM
PETERSMEYER GARY SDirectorOct 06Sale348.541,000348,5401,338Oct 07 05:06 PM
Lindell Jody SDirectorSep 16Option Exercise66.806,500434,20019,054Sep 17 05:21 PM
Lindell Jody SDirectorSep 16Sale338.696,5002,201,45312,554Sep 17 05:21 PM
White Albert G IIIPresident & CEOJul 08Buy278.231,000278,23041,430Jul 08 04:58 PM
Sheffield Holly REVP, CSOJul 08Buy280.20534149,6241,414Jul 08 04:57 PM
Sheffield Holly REVP, CSOJul 08Buy280.0035599,4001,285Jul 08 04:57 PM
Ricupati AgostinoSVP, Fin & Tax; Chief Actg OffJul 01Option Exercise0.0034802,148Jul 02 05:45 PM
Sheffield Holly REVP, CSOJun 12Buy283.18880249,198880Jun 15 04:43 PM
Ricupati AgostinoSVP, Fin & Tax; Chief Actg OffJun 11Buy281.471,000281,4701,800Jun 15 04:39 PM
Sheffield Holly REVP, CSOJun 04Option Exercise0.001,10501,383Jun 08 04:30 PM
Ricupati AgostinoSVP, Fin & Tax; Chief Actg OffFeb 03Option Exercise0.0055501,057Feb 04 04:59 PM
Golden RandalVP, General Counsel & Sec.Feb 03Option Exercise0.0061001,995Feb 04 04:58 PM
Auerbach Robert DPresident, CSIFeb 03Option Exercise0.0066604,582Feb 04 04:47 PM
Andrews Brian GSVP, CFO & TreasurerFeb 03Option Exercise0.0055501,935Feb 04 04:46 PM
Auerbach Robert DPresident, CSIJan 08Option Exercise0.001,90703,723Jan 10 06:15 PM
Ricupati AgostinoSVP, Fin & Tax; Chief Actg OffJan 08Option Exercise0.001,0650637Jan 10 06:15 PM
Andrews Brian GSVP, CFO & TreasurerJan 08Option Exercise0.0059501,438Jan 10 06:12 PM
Golden RandalVP, General Counsel & Sec.Jan 08Option Exercise0.0050201,520Jan 10 06:13 PM
Sheffield Holly REVP, CSOJan 08Option Exercise0.005890589Jan 10 06:11 PM
White Albert G IIIPresident & CEOJan 08Option Exercise0.00452039,454Jan 10 06:10 PM
McBride Daniel GEVP, COO & Pres-CooperVisionJan 08Option Exercise0.00708031,395Jan 10 06:09 PM
Lindell Jody SDirectorJan 06Option Exercise49.573,500173,49516,054Jan 07 04:57 PM
Lindell Jody SDirectorJan 06Sale321.013,5001,123,53412,554Jan 07 04:57 PM
PETERSMEYER GARY SDirectorJan 06Sale322.2925080,5731,338Jan 07 04:54 PM
KALKSTEIN MICHAELDirectorJan 02Option Exercise61.369,500582,91012,338Jan 06 05:44 PM
KALKSTEIN MICHAELDirectorJan 02Sale320.359,5003,043,3195,838Jan 06 05:44 PM
OMCL Omnicell, Inc. daily Stock Chart
Omnicell, Inc.
Index- P/E122.89 EPS (ttm)0.87 Insider Own2.10% Shs Outstand42.80M Perf Week4.70%
Market Cap4.44B Forward P/E34.16 EPS next Y3.13 Insider Trans-5.16% Shs Float41.74M Perf Month24.77%
Income37.90M PEG8.19 EPS next Q0.75 Inst Own- Short Float7.17% Perf Quarter56.17%
Sales891.30M P/S4.98 EPS this Y53.50% Inst Trans1.18% Short Ratio6.18 Perf Half Y59.60%
Book/sh21.46 P/B4.98 EPS next Y31.34% ROA2.80% Target Price93.25 Perf Year31.99%
Cash/sh15.15 P/C7.05 EPS next 5Y15.00% ROE4.30% 52W Range54.24 - 108.32 Perf YTD30.68%
Dividend- P/FCF35.86 EPS past 5Y11.40% ROI7.30% 52W High-1.41% Beta0.99
Dividend %- Quick Ratio3.70 Sales past 5Y15.30% Gross Margin46.60% 52W Low96.88% ATR3.30
Employees2700 Current Ratio4.10 Sales Q/Q-6.60% Oper. Margin4.20% RSI (14)83.70 Volatility3.10% 3.61%
OptionableYes Debt/Eq0.50 EPS Q/Q-56.60% Profit Margin4.30% Rel Volume0.70 Prev Close107.75
ShortableYes LT Debt/Eq0.50 EarningsOct 27 AMC Payout0.00% Avg Volume484.38K Price106.79
Recom2.10 SMA2011.07% SMA5025.55% SMA20044.57% Volume338,098 Change-0.89%
Jul-07-20Initiated Stephens Overweight $90
Feb-07-20Reiterated Dougherty & Company Buy $92 → $100
Nov-21-19Reiterated Dougherty & Company Buy $90 → $92
Jul-26-19Upgrade Craig Hallum Hold → Buy $85
Mar-07-19Reiterated Dougherty & Company Buy $78 → $90
Jun-29-18Resumed The Benchmark Company Buy $63
Sep-05-17Reiterated The Benchmark Company Buy $55 → $67
Jul-28-17Reiterated Dougherty & Company Buy $45 → $49
Apr-21-17Downgrade Piper Jaffray Overweight → Neutral
Jan-19-17Initiated Dougherty & Company Buy $44
Dec-06-16Reiterated The Benchmark Company Buy $39 → $55
Jul-07-16Reiterated FBR Capital Outperform $35 → $40
Mar-21-16Reiterated Topeka Capital Markets Buy $38 → $37
Jan-07-16Initiated The Benchmark Company Buy $33
Nov-16-15Reiterated Topeka Capital Markets Buy $40 → $38
Oct-30-15Reiterated FBR Capital Outperform $40 → $35
Sep-28-15Upgrade Sidoti Neutral → Buy
Jul-31-15Reiterated Topeka Capital Markets Buy $39 → $40
Jul-31-15Reiterated Oppenheimer Outperform $44 → $42
Jun-18-15Initiated Oppenheimer Outperform $44
Nov-12-20 03:55PM  
Nov-11-20 08:01AM  
Nov-10-20 08:01AM  
Nov-09-20 08:01AM  
Nov-06-20 05:27PM  
Nov-03-20 09:14AM  
Oct-27-20 08:31PM  
Oct-26-20 10:18AM  
Oct-22-20 08:01AM  
Oct-20-20 12:31PM  
Oct-06-20 12:38PM  
Oct-01-20 04:01PM  
Sep-29-20 04:53PM  
Sep-23-20 11:24AM  
Sep-22-20 07:00AM  
Sep-08-20 01:13PM  
Sep-01-20 04:15PM  
Aug-27-20 11:31AM  
Aug-18-20 10:51AM  
Aug-17-20 09:10AM  
Aug-12-20 10:02AM  
Aug-11-20 12:04PM  
Jul-29-20 09:54AM  
Jul-28-20 10:01PM  
Jul-21-20 04:01PM  
Jul-20-20 08:00AM  
Jul-16-20 12:32PM  
Jun-25-20 08:13AM  
Jun-24-20 10:38AM  
Jun-11-20 11:40AM  
Jun-05-20 10:02AM  
May-08-20 10:08AM  
May-07-20 04:01PM  
May-01-20 04:05PM  
Apr-30-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 12:31PM  
Apr-01-20 11:40AM  
Mar-27-20 10:47AM  
Mar-16-20 05:57PM  
Mar-12-20 09:17AM  
Mar-07-20 11:31AM  
Mar-05-20 08:30AM  
Feb-19-20 08:06AM  
Feb-13-20 08:49AM  
Feb-12-20 11:40AM  
Feb-10-20 08:00AM  
Feb-07-20 09:31AM  
Feb-06-20 05:25PM  
Feb-03-20 08:01AM  
Jan-30-20 04:05PM  
Jan-28-20 10:49AM  
Jan-26-20 11:00PM  
Jan-21-20 09:21AM  
Jan-20-20 07:34AM  
Jan-16-20 07:01AM  
Jan-15-20 06:48AM  
Jan-14-20 08:36AM  
Jan-13-20 08:39AM  
Jan-09-20 05:52AM  
Jan-07-20 11:12AM  
Jan-06-20 04:24PM  
Jan-03-20 10:48AM  
Dec-31-19 10:53AM  
Dec-30-19 11:47AM  
Dec-27-19 10:16AM  
Dec-18-19 08:21AM  
Dec-17-19 08:22AM  
Dec-14-19 07:47PM  
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIPPS RANDALL AChairman, President and CEONov 23Option Exercise0.0012,6000164,716Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 23Sale105.4012,6001,328,030152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Option Exercise0.002,4000154,516Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Sale105.012,400252,034152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 04Sale89.5911,4351,024,439229,113Nov 04 05:48 PM
LIPPS RANDALL AChairman, President and CEOSep 16Sale75.6413,7431,039,501240,548Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOSep 15Sale75.011,400105,009254,291Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOJul 29Sale75.153,718279,398148,398Jul 30 12:42 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerJun 16Sale67.702,125143,86931,260Jun 17 05:09 PM
LIPPS RANDALL AChairman, President and CEOMay 14Option Exercise60.395,500332,145162,352May 14 06:42 PM
LIPPS RANDALL AChairman, President and CEOMay 13Option Exercise59.362,450145,432156,852May 14 06:42 PM
LIPPS RANDALL AChairman, President and CEOApr 03Sale66.115,000330,566259,409Apr 03 04:58 PM
LIPPS RANDALL AChairman, President and CEOApr 02Sale62.935,000314,631264,409Apr 03 12:13 PM
Bauer Joanne BDirectorFeb 19Sale88.422,919258,11215,916Feb 19 06:29 PM
Kuipers Peter J.Executive V P& CFOFeb 14Option Exercise0.0011,267070,285Feb 18 02:38 PM
Kuipers Peter J.Executive V P& CFOFeb 14Sale89.7911,2671,011,63759,018Feb 18 02:38 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerFeb 10Option Exercise0.002,833026,474Feb 11 12:16 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerFeb 10Sale86.372,833244,69823,641Feb 11 12:16 PM
LIPPS RANDALL AChairman, President and CEOJan 07Option Exercise0.0024,0000140,466Jan 08 04:28 PM
LIPPS RANDALL AChairman, President and CEOJan 07Sale81.435,000407,143284,409Jan 08 04:28 PM
LIPPS RANDALL AChairman, President and CEOJan 07Sale81.4124,0001,953,852116,466Jan 08 04:28 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerDec 16Sale80.591,356109,28123,641Dec 16 04:47 PM
JOHNSTON DAN SEVP & Chief Legal & AdminNov 29Option Exercise0.006,250034,076Dec 02 02:31 PM
JOHNSTON DAN SEVP & Chief Legal & AdminNov 29Sale80.389,086730,29924,990Dec 02 02:31 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.